What is HC Wainwright’s Estimate for RVPH FY2024 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – HC Wainwright raised their FY2024 earnings per share (EPS) estimates for Reviva Pharmaceuticals in a report issued on Wednesday, January 22nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.00) per share for the year, up from their previous estimate of ($1.04). HC Wainwright currently has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.99) per share. HC Wainwright also issued estimates for Reviva Pharmaceuticals’ Q4 2024 earnings at ($0.25) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.16) EPS and FY2025 earnings at ($0.82) EPS.

Other analysts have also issued research reports about the stock. D. Boral Capital restated a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Friday, January 10th. Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Finally, Roth Mkm assumed coverage on Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a “buy” rating and a $7.00 price target for the company. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $11.40.

Reviva Pharmaceuticals Stock Up 1.1 %

RVPH stock opened at $1.91 on Friday. The stock’s 50 day moving average is $1.71 and its two-hundred day moving average is $1.34. Reviva Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $4.83. The company has a market capitalization of $63.87 million, a PE ratio of -1.72 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently modified their holdings of RVPH. Drive Wealth Management LLC bought a new stake in Reviva Pharmaceuticals in the fourth quarter valued at $36,000. EMC Capital Management increased its holdings in shares of Reviva Pharmaceuticals by 142.0% in the 4th quarter. EMC Capital Management now owns 44,535 shares of the company’s stock worth $81,000 after acquiring an additional 26,134 shares during the period. Finally, Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after purchasing an additional 42,376 shares during the last quarter. Institutional investors own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.